Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
Subscribe To Our Newsletter & Stay Updated
